Dupilumab in patients with atopic dermatitis: assessing treatment response, clinical features and potential biomarkers in real-life

Conclusions. In this cohort, none of the evaluated biomarkers at baseline were associated with a better/earlier clinical response to dupilumab. Dupilumab treatment for 52 weeks resulted in a significant and sustained reduction in blood levels of total IgE and allergen-specific IgE to aeroallergens. The potential long-term clinical benefit of these effects, even after discontinuing dupilumab therapy in patients with AD, should be explored to a greater extent.PMID:38591168 | DOI:10.23822/EurAnnACI.1764-1489.341
Source: European Annals of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research